NCT05904717
Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Sep 30, 2024 to Jul 31, 2026 Show 4 more changesShow less
- Eligibility criteria expanded, about 55 words
- Trial completed
- Study completion date changed from estimate of Sep 30, 2026 to Sep 14, 2026
- Site details revised at 1 of 3 sites
- Minor Study completion date: Jan 31, 2026 to Sep 30, 2026v4
- Notable Eligibility criteria expanded, about 100 words
- Trial status: Recruiting to Active, Not Recruiting
- Study sites: 2 to 3
- Study completion date: Jan 31, 2025 to Jan 31, 2026
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jul 1, 2023 to Nov 8, 2023
- Site details revised at 2 of 2 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
To assess the reduction of microglial activation across striato-cortical regions
Timeframe: Up to Week 12
To assess the safety and tolerability of PXS-4728A as determined by adverse events (AEs)
Timeframe: Up to Week 24
Secondary (1)
To assess the reduction of microglial activation across the whole brain and cortical and subcortical regions of interest (ROIs)
Arms and interventions
A (PXS-4728)Experimental
IP Name: PXS-4728 Dosage: 15 mg Mode: oral administration (PO)
B (Matching Placebo)Placebo comparator
Matching placebo to PXS-4728
Drugs: PXS-4728 (A), Matching Placebo (B)
Sites
3 sites in 2 countries
Australia 2, United Kingdom 1